Acute Mesenteric Venous Thrombosis: A Better Outcome Achieved Through Improved Imaging Techniques and a Changed Policy of Clinical Management

Zhang, J; Duan, Zhi-quan; Song, Qingbin; Luo, Yanwei; Xin, Shijie; Q, Zhang

doi:10.1016/j.ejvs.2004.06.001

Cited by 64 publications

(42 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,[5][6][7] The proportion of patients with idiopathic cases decreases with more extensive evaluation. 8 Malignancies including myeloproliferative neoplasms are the most common form of prothrombotic disorders associated with MVT.…”

Section: Incidence and Etiologymentioning

confidence: 99%

“…Increasing use of CT scan for abdominal pain in the emergency department is associated with decrease in the time to diagnosis from 1 week to 1 day. 2 A filling defect in the mesenteric vein is the most common finding in patients with MVT. Bowel wall thickening, pneumatosis intestinalis, portal vein gas and persistent enhancement of the bowel wall suggest bowel wall ischemia.…”

Section: Diagnosismentioning

confidence: 99%

“…Advances in the radiology techniques and anticoagulation have led to improved diagnosis and outcomes. 2 …”

Section: Esenteric Venous Thrombosis (Mvt) Is An Un-mentioning

confidence: 99%

See 2 more Smart Citations

Mesenteric Venous Thrombosis

Singal

Kamath

Tefferi

2013

Mayo Clinic Proceedings

192

198

View full text Add to dashboard Cite

Section: Incidence and Etiologymentioning

confidence: 99%

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Mesenteric Venous Thrombosis

Singal

Kamath

Tefferi

2013

Mayo Clinic Proceedings

192

198

View full text Add to dashboard Cite

“…Several small, retrospective investigations have demonstrated the benefit of anticoagulation in acute MVT. 12 However, these patients may require further intervention such as thrombolysis or surgery to prevent death. In chronic MVT, anticoagulation may promote recanalization and prevents new thrombosis.…”

Section: Anticoagulationmentioning

confidence: 99%

Mesenteric Venous Thrombosis

2015

View full text Add to dashboard Cite

“…Overall, ASMVT remains an intractable disease with unsatisfactory outcome. The requirement of laparotomy and the mortality rate following therapy with traditional anticoagulant medicines, including unfractionated heparin (UFH), low molecular weight heparin (LMWH) and warfarin, remain high (2,6). The application of these medications is limited due to the occurrence of heparin-associated thrombocytopenia (7).…”

Section: Introductionmentioning

confidence: 99%

Early initiation of argatroban therapy in the management of acute superior mesenteric venous thrombosis

Zeng

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Acute superior mesenteric venous thrombosis (ASMVT) is an intractable disease with poor prognosis. Argatroban, a direct thrombin inhibitor, may be a novel anticoagulant method in the therapy of ASMVT. The aim of the present study was to assess the efficacy and safety of early argatroban therapy in ASMVT patients. The current retrospective study reviewed a consecutive series of ASMVT patients receiving early argatroban therapy during hospitalization between March 2013 and April 2014, with 18 ASMVT patients included in the study. Of these, 16 patients without hepatic dysfunction underwent anticoagulant therapy with argatroban with a mean dose of 1.57±0.34 µg/kg/min and a mean duration of 12.2±3.7 days, while their activated partial thromboplastin time (aPTT) was elevated to 1.95±0.26 times the baseline value. In addition, 2 hepatic dysfunction patients received therapy with a dose of 0.41 µg/kg/min and 0.46 µg/kg/min, and with aPTT of 1.68 and 1.62 times the baseline value, respectively. Overall, 94% (n=17) of the patients presented clinical improvement, while 88% (n=16) of patients presented partially or completely dissolved thrombus in contrast-enhanced computed tomography images. The incidence of surgery and bowel resection was 6% (excluding 1 case with intestinal necrosis detected on admission). Furthermore, 11% (n=2) of patients experienced a bleeding episode, however no major bleeding or mortality occurred during hospitalization. During the follow-up, the mortality and the recurrence rate were 6% and 11%, respectively. In conclusion, early initiation of argatroban treatment may be an effective and safe therapy in ASMVT, manifesting efficient resolution of the thrombus, rapid improvement of symptoms, low incidence of bowel resection and bleeding complication, and low mortality rate.

show abstract

Acute Mesenteric Venous Thrombosis: A Better Outcome Achieved Through Improved Imaging Techniques and a Changed Policy of Clinical Management

Abstract: Recent improvements in imaging techniques and better understanding of the aetiology have led to a dramatic change in the principle and policy of clinical management for acute MVT, which leads to a more favourable outcome of acute MVT.

Cited by 64 publications

References 11 publications

Mesenteric Venous Thrombosis

Mesenteric Venous Thrombosis

Mesenteric Venous Thrombosis

Early initiation of argatroban therapy in the management of acute superior mesenteric venous thrombosis

Contact Info

Product

Resources

About